Review of Ruxolitinib in the Treatment of Atopic Dermatitis
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221103282
Abstract: Objective To review the pharmacokinetics, efficacy, and safety of a newly approved topical Janus kinase 1 (JAK) inhibitor, ruxolitinib (RUX), in patients with atopic dermatitis (AD). Data Sources A literature search was completed May 1,… read more here.
Keywords: ruxolitinib; review; rux; atopic dermatitis ... See more keywords